Cargando…

ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas

Gliomas are the most aggressive primary intracranial malignancies with poor overall survival. ITGA5 is one member of the integrin adhesion molecule family and is implicated in cancer metastasis and oncogenesis. However, few studies have explored the association between tumor immune microenvironment...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shuyu, Zhang, Nan, Liu, Shiyang, Zhang, Hao, Liu, Jiajing, Qi, Yiwei, Zhang, Qi, Li, Xingrui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971292/
https://www.ncbi.nlm.nih.gov/pubmed/35371978
http://dx.doi.org/10.3389/fonc.2022.844144
_version_ 1784679602911707136
author Li, Shuyu
Zhang, Nan
Liu, Shiyang
Zhang, Hao
Liu, Jiajing
Qi, Yiwei
Zhang, Qi
Li, Xingrui
author_facet Li, Shuyu
Zhang, Nan
Liu, Shiyang
Zhang, Hao
Liu, Jiajing
Qi, Yiwei
Zhang, Qi
Li, Xingrui
author_sort Li, Shuyu
collection PubMed
description Gliomas are the most aggressive primary intracranial malignancies with poor overall survival. ITGA5 is one member of the integrin adhesion molecule family and is implicated in cancer metastasis and oncogenesis. However, few studies have explored the association between tumor immune microenvironment and ITGA5 expression level in gliomas. Firstly, we analyzed 3,047 glioma patient samples collected from the TCGA, the CGGA, and the GEO databases, proving that high ITGA5 expression positively related to aggressive clinicopathological features and poor survival in glioma patients. Then, based on the ITGA5 level, immunological characteristics and genomic alteration were explored through multiple algorithms. We observed that ITGA5 was involved in pivotal oncological pathways, immune-related processes, and distinct typical genomic alterations in gliomas. Notably, ITGA5 was found to engage in remolding glioma immune infiltration and immune microenvironment, manifested by higher immune cell infiltration when ITGA5 is highly expressed. We also demonstrated a strong correlation between ITGA5 and immune checkpoint molecules that may be beneficial from immune checkpoint blockade strategies. In addition, ITGA5 was found to be a robust and sensitive indicator for plenty of chemotherapy drugs through drug sensitivity prediction. Altogether, our comprehensive analyses deciphered the prognostic, immunological, and therapeutic value of ITGA5 in glioma, thus improving individual and precise therapy for combating gliomas.
format Online
Article
Text
id pubmed-8971292
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89712922022-04-02 ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas Li, Shuyu Zhang, Nan Liu, Shiyang Zhang, Hao Liu, Jiajing Qi, Yiwei Zhang, Qi Li, Xingrui Front Oncol Oncology Gliomas are the most aggressive primary intracranial malignancies with poor overall survival. ITGA5 is one member of the integrin adhesion molecule family and is implicated in cancer metastasis and oncogenesis. However, few studies have explored the association between tumor immune microenvironment and ITGA5 expression level in gliomas. Firstly, we analyzed 3,047 glioma patient samples collected from the TCGA, the CGGA, and the GEO databases, proving that high ITGA5 expression positively related to aggressive clinicopathological features and poor survival in glioma patients. Then, based on the ITGA5 level, immunological characteristics and genomic alteration were explored through multiple algorithms. We observed that ITGA5 was involved in pivotal oncological pathways, immune-related processes, and distinct typical genomic alterations in gliomas. Notably, ITGA5 was found to engage in remolding glioma immune infiltration and immune microenvironment, manifested by higher immune cell infiltration when ITGA5 is highly expressed. We also demonstrated a strong correlation between ITGA5 and immune checkpoint molecules that may be beneficial from immune checkpoint blockade strategies. In addition, ITGA5 was found to be a robust and sensitive indicator for plenty of chemotherapy drugs through drug sensitivity prediction. Altogether, our comprehensive analyses deciphered the prognostic, immunological, and therapeutic value of ITGA5 in glioma, thus improving individual and precise therapy for combating gliomas. Frontiers Media S.A. 2022-03-18 /pmc/articles/PMC8971292/ /pubmed/35371978 http://dx.doi.org/10.3389/fonc.2022.844144 Text en Copyright © 2022 Li, Zhang, Liu, Zhang, Liu, Qi, Zhang and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Shuyu
Zhang, Nan
Liu, Shiyang
Zhang, Hao
Liu, Jiajing
Qi, Yiwei
Zhang, Qi
Li, Xingrui
ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas
title ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas
title_full ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas
title_fullStr ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas
title_full_unstemmed ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas
title_short ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas
title_sort itga5 is a novel oncogenic biomarker and correlates with tumor immune microenvironment in gliomas
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971292/
https://www.ncbi.nlm.nih.gov/pubmed/35371978
http://dx.doi.org/10.3389/fonc.2022.844144
work_keys_str_mv AT lishuyu itga5isanoveloncogenicbiomarkerandcorrelateswithtumorimmunemicroenvironmentingliomas
AT zhangnan itga5isanoveloncogenicbiomarkerandcorrelateswithtumorimmunemicroenvironmentingliomas
AT liushiyang itga5isanoveloncogenicbiomarkerandcorrelateswithtumorimmunemicroenvironmentingliomas
AT zhanghao itga5isanoveloncogenicbiomarkerandcorrelateswithtumorimmunemicroenvironmentingliomas
AT liujiajing itga5isanoveloncogenicbiomarkerandcorrelateswithtumorimmunemicroenvironmentingliomas
AT qiyiwei itga5isanoveloncogenicbiomarkerandcorrelateswithtumorimmunemicroenvironmentingliomas
AT zhangqi itga5isanoveloncogenicbiomarkerandcorrelateswithtumorimmunemicroenvironmentingliomas
AT lixingrui itga5isanoveloncogenicbiomarkerandcorrelateswithtumorimmunemicroenvironmentingliomas